Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» sickle cell disease
sickle cell disease
Court ruling on bluebird bio’s gene therapy marketing campaign 'sparks' dismay at Roche's Spark
Fierce Pharma
Thu, 01/27/22 - 10:38 am
Bluebird Bio
gene therapy
sickle cell disease
Roche
Spark Therapeutics
JPM 2022: Bluebird bio hopes for clear skies ahead as it gears up for trio of gene therapy launches
Fierce Pharma
Thu, 01/13/22 - 10:32 pm
JPMHC 2022
Bluebird Bio
gene therapy
sickle cell disease
beti-cel
Sanofi cuts ties with Sangamo, sharpening focus on 'off-the-shelf' cell therapy
BioPharma Dive
Thu, 01/6/22 - 12:39 pm
Sanofi
Sangamo Therapeutics
cell therapy
sickle cell disease
4 Biotechs That Were Winners at ASH
Motley Fool
Mon, 01/3/22 - 10:38 am
ASH2021
Bristol Myers Squibb
Agios Pharmaceuticals
Forma Therapeutics
Bluebird Bio
sickle cell disease
Multiple Myeloma
First sickle cell patient treated with CRISPR gene-editing still thriving
NPR
Fri, 12/31/21 - 11:07 am
CRISPR
gene editing
sickle cell disease
bluebird bio Announces Partial Clinical Hold for Patients Under 18 in Sickle Cell Gene Therapy Clinical Program
Yahoo Finance
Mon, 12/20/21 - 10:54 am
Bluebird Bio
lovo-cel
gene therapy
sickle cell disease
FDA
clinical hold
clinical trials
ASH 2021 – Bluebird looks to revive Lentiglobin
EP Vantage
Mon, 12/13/21 - 10:34 am
Bluebird Bio
LentiGlobin
ASH2021
sickle cell disease
Global Blood takes on gene therapy
EP Vantage
Thu, 10/28/21 - 10:36 am
Global Blood Therapeutics
GBT021601
Oxbryta
gene therapy
ASH2021
sickle cell disease
With LentiGlobin cleared by FDA, bluebird lifts EU marketing hold on gene therapy using the same delivery mechanism
Endpoints
Fri, 07/9/21 - 09:54 am
Bluebird Bio
LentiGlobin
sickle cell disease
Zynteglo
Europe
beta thalassemia
Novartis, GBT sickle cell drugs face coverage hurdles as gene therapy threats loom: survey
Fierce Pharma
Wed, 06/30/21 - 12:09 am
Novartis
Adakveo
Global Blood Therapeutics
Oxbryta
sickle cell disease
gene therapy
With sickle cell disease study in sight, Graphite Bio draws up a $238M IPO
MedCity News
Sun, 06/27/21 - 10:47 pm
Graphite Bio
IPOs
sickle cell disease
Elevation Oncology
Monte Rosa
Forma builds case for FT-4202 in competitive sickle cell space
Fierce Biotech
Tue, 03/30/21 - 11:56 am
Forma Therapeutics
sickle cell disease
FT-4202
clinical trials
With all the buzz in gene therapy, Sanofi offloads two small molecule sickle cell programs from $11.6B buyout to Global Blood Therapeutics
Endpoints
Tue, 03/16/21 - 10:55 am
Sanofi
sickle cell disease
gene therapy
gene editing
Global Blood Therapeutics
In race for in vivo sickle cell cure, Intellia unveils (very) early proof-of-concept
Endpoints
Thu, 03/11/21 - 10:35 am
Intellia
CRISPR
sickle cell disease
Bluebird seeks gene therapy trial restart after cancer scare
Pharmaforum
Wed, 03/10/21 - 11:27 am
Bluebird Bio
LentiGlobin
gene therapy
sickle cell disease
AML
Novartis and the Gates Foundation aim to create a more practical gene therapy for sickle cell patients around the world
Stat
Wed, 02/17/21 - 10:41 am
Novartis
Gates Foundation
gene therapy
sickle cell disease
Bluebird stops studies of sickle cell gene therapy after new cancer cases
BioPharma Dive
Tue, 02/16/21 - 11:19 am
Bluebird Bio
gene therapy
sickle cell disease
leukemia
clinical trials
Imara attempts to spin weak data into an 'encouraging' result — but investors aren't having it
Endpoints
Wed, 01/6/21 - 11:07 pm
Imara
IMR-687
sickle cell disease
1st Patients To Get CRISPR Gene-Editing Treatment Continue To Thrive
NPR
Tue, 12/15/20 - 10:32 am
CRISPR
gene editing
sickle cell disease
ASH 2020 – Forma gets an early edge over Agios in sickle cell disease
EP Vantage
Tue, 12/8/20 - 10:30 am
ASH2020
Forma Therapeutics
Agios
sickle cell disease
FT-4202
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
next ›
last »